108 related articles for article (PubMed ID: 1930575)
1. Influence of cefpodoxime on selected immunological functions and bacterial pathogenicity factors in vitro.
Schubert S; Ullmann U
Zentralbl Bakteriol; 1991 Jun; 275(2):233-40. PubMed ID: 1930575
[TBL] [Abstract][Full Text] [Related]
2. Interaction of ceftriaxone with human polymorphonuclear neutrophil function.
Labro MT; Babin-Chevaye C; Pochet I; Hakim J
J Antimicrob Chemother; 1987 Dec; 20(6):849-55. PubMed ID: 2831183
[TBL] [Abstract][Full Text] [Related]
3. Effects of cefaclor, cefetamet and Ro 40-6890 on inflammatory responses of human granulocytes.
Scheffer J; Knöller J; Cullmann W; König W
J Antimicrob Chemother; 1992 Jul; 30(1):57-66. PubMed ID: 1429337
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and ex vivo susceptibility of cefpodoxime proxetil in patients receiving continuous ambulatory peritoneal dialysis.
Johnson CA; Ateshkadi A; Zimmerman SW; Hughes GS; Craig WA; Carey PM; Borin MT
Antimicrob Agents Chemother; 1993 Dec; 37(12):2650-5. PubMed ID: 8109931
[TBL] [Abstract][Full Text] [Related]
5. [Study of the bactericidal effect of cefpodoxime using an in vitro pharmacokinetic model].
Caisson A; Chantot JF
Pathol Biol (Paris); 1991 Oct; 39(8):774-9. PubMed ID: 1762835
[TBL] [Abstract][Full Text] [Related]
6. Enhanced susceptibility of Staphylococcus aureus pretreated with cefepime and cefpodoxime to leukocyte activity.
Herrera I; Martinez P; Perez P; Garcia Y; Gomez-Lus ML; Prieto J
J Chemother; 1995 Nov; 7 Suppl 4():23-5. PubMed ID: 8904094
[No Abstract] [Full Text] [Related]
7. Immunomodulating properties of newer cephalosporins: a preliminary classification.
Labro M; Bryskier A
Chemioterapia; 1987 Jun; 6(2 Suppl):219-21. PubMed ID: 3334561
[No Abstract] [Full Text] [Related]
8. Antibacterial activity of cefpodoxime in vitro.
Liu YC; Huang WK; Cheng DL
Chemotherapy; 1997; 43(1):21-6. PubMed ID: 8996737
[TBL] [Abstract][Full Text] [Related]
9. Effect of ceftriaxone on bacterial killing by human neutrophils in vitro.
Labro M; Babin-Chevaye C; Pochet I; Hakim J
Chemioterapia; 1987 Jun; 6(2 Suppl):234-6. PubMed ID: 3334563
[No Abstract] [Full Text] [Related]
10. In-vitro evaluation of cefpodoxime.
Valentini S; Coratza G; Rossolini GM; Massidda O; Satta G
J Antimicrob Chemother; 1994 Mar; 33(3):495-508. PubMed ID: 8040114
[TBL] [Abstract][Full Text] [Related]
11. [Bacteriological, pharmacokinetic and clinical studies on cefpodoxime proxetil in the pediatric field].
Toyonaga Y; Koizumi M; Imai H; Sugita M; Takahashi T; Fukushima Y; Yamasaki M; Hori M
Jpn J Antibiot; 1989 Jul; 42(7):1519-46. PubMed ID: 2810728
[TBL] [Abstract][Full Text] [Related]
12. The relationship between luminol chemiluminescence and killing of staphylococcus aureus by neutrophil granulocytes.
Ewetz L; Palmblad J; Thore A
Blut; 1981 Dec; 43(6):373-81. PubMed ID: 7332786
[TBL] [Abstract][Full Text] [Related]
13. Effects of antibiotics on polymorphonuclear leukocyte chemiluminescence and chemotaxis.
Oleske JM; de la Cruz A; Ahdieh H; Sorvino D; La Braico J; Cooper R; Singh R; Lin R; Minnefor A
J Antimicrob Chemother; 1983 Oct; 12 Suppl C():35-8. PubMed ID: 6196344
[TBL] [Abstract][Full Text] [Related]
14. Effect of ciprofloxacin on phagocytosis.
Forsgren A; Bergkvist PI
Eur J Clin Microbiol; 1985 Dec; 4(6):575-8. PubMed ID: 2936604
[TBL] [Abstract][Full Text] [Related]
15. [RU 51807 (cefpodoxime proxetil). In vitro and in vivo antibacterial activity of a new orally administered active cephalosporin].
Chantot JF; Mauvais P
Pathol Biol (Paris); 1991 Jan; 39(1):17-27. PubMed ID: 1901403
[TBL] [Abstract][Full Text] [Related]
16. An outbreak of a CTX-M-type beta-lactamase-producing Klebsiella pneumoniae: the importance of using cefpodoxime to detect extended-spectrum beta-lactamases.
Brenwald NP; Jevons G; Andrews JM; Xiong JH; Hawkey PM; Wise R
J Antimicrob Chemother; 2003 Jan; 51(1):195-6. PubMed ID: 12493817
[No Abstract] [Full Text] [Related]
17. Cefpodoxime proxetil, its in vitro antibacterial activity, affinity to bacterial penicillin-binding proteins, and synergy of bactericidal activity with serum complement and mouse-cultured macrophages.
Yokota T; Suzuki E; Arai K
Drugs Exp Clin Res; 1988; 14(8):495-500. PubMed ID: 3073932
[TBL] [Abstract][Full Text] [Related]
18. [Comparison of pharmacokinetics/pharmacodynamics of cefdinir, cefpodoxime proxetil and cefaclor against common bacteria of community acquired infections].
Xiao YH; Gao L; Li Y; Lü Y; Liu J; Liu Y
Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1867-71. PubMed ID: 15631795
[TBL] [Abstract][Full Text] [Related]
19. Cefpodoxime: comparative antibacterial activity, influence of growth conditions, and bactericidal activity.
Knothe H; Shah PM; Eckardt O
Infection; 1991; 19(5):370-6. PubMed ID: 1800379
[TBL] [Abstract][Full Text] [Related]
20. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
